

Comparison of Video-Assisted Thoracoscopic Lung Biopsy vs. Bronchopulmonary Alveolar Lavage for Diagnosis of Fungal Disease in Pediatric Oncology Patients



Jeffrey Compton, MS; Lorrie Burkhalter, BS; Shannon Cohn, MD; Joseph T. Murphy, MD
Division of Pediatric Surgery, University of Texas Southwestern Medical Center
Children's HealthSM Children's Medical Center

MD Ch

Introduction

- Pulmonary fungal infection is a known complication of the treatment of pediatric malignancy
- Accurate diagnosis relies on culture of fungi from pulmonary lavage fluid or open biopsy of lung parenchyma
- Minimally invasive lung biopsy techniques have decreased the morbidity/mortality of diagnostic lung biopsy procedures
- Aim: To compare diagnostic yields (DY)
 of bronchopulmonary lavage (BAL) lung
 washings vs. video-assisted thoracoscopic
 surgery (VATS) tissue biopsy

Methods

With IRB approval, the Oncology Registry and Electronic Medical Records at our institution were queried for pediatric oncology patients (age < 18yrs) who have had either BAL and/or VATS for assessment of possible pulmonary fungal infection as suggested by CT imaging during treatment for various malignancies from March 2005 to May 2014 for a retrospective analysis.

Demographics

Table 1.				
Characteristic	All Patients (n=106)	BAL Procedures (n=116)	VATS Procedures (n=30)	
Sex				
Male	55	59	15	
Female	51	57	15	
Race				
White	62	69	21	
African American	15	15	5	
Hispanic	10	12	2	
Asian	2	2	0	
Other	9	9	2	
Unknown	8	9	0	
Age at procedures				
Mean ± SD	8.8 ± 4.8	8.6 ± 4.6	9.7 ± 5.7	
Median (range)	8.4 (0.3-17.9)	8.3 (0.3-17.9)	10.2 (1.7-17.5)	

Table 2. Procedure count and diagnostic yield for corresponding oncological diagnosis

Oncological Diagnosis Procedures (n) Dry (%) Procedures (%) Dry (%) ALL 53 65 27.7 14 21.4 AML 24 24 25.0 8 62.5 Lymphoma 6 9 0.0 2 0.0 Neuroblastoma 3 3 33.3 0 n/a Hepatoblastoma 2 1 0.0 1 0.0 Myeloid Sarcoma 2 1 100.0 1 100.0 Wilms Tumor 2 2 0.0 0 n/a Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 0 n/a Glioblastoma 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 1 0.0 0 n/a			BAL		VATS	
ALL 53 65 27.7 14 21.4 AML 24 24 25.0 8 62.5 Lymphoma 6 9 0.0 2 0.0 Neuroblastoma 3 3 33.3 0 n/a Hepatoblastoma 2 1 0.0 1 0.0 Myeloid Sarcoma 2 1 100.0 1 100.0 Wilms Tumor 2 2 0.0 0 n/a Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 Glioblastoma 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Lymphoproliferative Disorder 1 2 50.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 <td></td> <td>Patients</td> <td></td> <td>DY</td> <td></td> <td>DY</td>		Patients		DY		DY
AML 24 24 25.0 8 62.5 Lymphoma 6 9 0.0 2 0.0 Neuroblastoma 3 3 33.3 0 n/a Hepatoblastoma 2 1 0.0 1 0.0 Myeloid Sarcoma 2 1 100.0 1 100.0 Wilms Tumor 2 2 0.0 0 n/a Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 Glioblastoma 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Lymphoproliferative Disorder 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 10.0 0 n/a Osteosarcoma/Lymphoma	Oncological Diagnosis	(n)	(n)	(%)	(n)	(%)
Lymphoma 6 9 0.0 2 0.0 Neuroblastoma 3 3 33.3 0 n/a Hepatoblastoma 2 1 0.0 1 0.0 Myeloid Sarcoma 2 1 100.0 1 100.0 Wilms Tumor 2 2 0.0 0 n/a Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 0	ALL	53	65	27.7	14	21.4
Neuroblastoma 3 3 33.3 0 n/a Hepatoblastoma 2 1 0.0 1 0.0 Myeloid Sarcoma 2 1 100.0 1 100.0 Wilms Tumor 2 2 2 0.0 0 n/a Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 Glioblastoma 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 1 100.0 0 n/a	AML	24	24	25.0	8	62.5
Hepatoblastoma 2 1 0.0 1 0.0 Myeloid Sarcoma 2 1 100.0 1 100.0 Wilms Tumor 2 2 0.0 0 n/a Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 Glioblastoma 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 n/a Myelodysplastic Syndrome 1 1 10.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 n/a Refractory Bilineage Leukemia 1 1 10.0 0	Lymphoma	6	9	0.0	2	0.0
Myeloid Sarcoma 2 1 100.0 1 100.0 Wilms Tumor 2 2 0.0 0 n/a Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 Glioblastoma 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 0 n/a Refractory Bilineage Leukemia 1 1 100.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 </td <td>Neuroblastoma</td> <td>3</td> <td>3</td> <td>33.3</td> <td>0</td> <td>n/a</td>	Neuroblastoma	3	3	33.3	0	n/a
Wilms Tumor 2 2 0.0 0 n/a Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 Glioblastoma 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 0 n/a Refractory Bilineage Leukemia 1 1 100.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 n/a	Hepatoblastoma	2	1	0.0	1	0.0
Biphenotypic Leukemia 1 1 0.0 0 n/a Ewing Sarcoma 1 0 n/a 1 0.0 Glioblastoma 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 0 n/a Refractory Bilineage Leukemia 1 1 100.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 n/a	Myeloid Sarcoma	2	1	100.0	1	100.0
Ewing Sarcoma 1 0 n/a 1 0.0 Glioblastoma 1 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 0 n/a Refractory Bilineage Leukemia 1 1 100.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 n/a	Wilms Tumor	2	2	0.0	0	n/a
Glioblastoma 1 1 0.0 0 n/a Inflammatory Myofibroblastic Tumor 1 0 n/a 1 0.0 Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 Pilocystic Astrocytoma 1 1 100.0 0 n/a Refractory Bilineage Leukemia 1 1 0.0 0 n/a Soft Tissue Sarcoma	Biphenotypic Leukemia	1	1	0.0	0	n/a
Inflammatory Myofibroblastic Tumor Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 Pilocystic Astrocytoma 1 1 100.0 0 n/a Refractory Bilineage Leukemia 1 1 0.0 0 n/a Soft Tissue Sarcoma	Ewing Sarcoma	1	0	n/a	1	0.0
Langerhan's Histocytosis 1 1 0.0 0 n/a Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 0 n/a Pilocystic Astrocytoma 1 1 100.0 0 n/a Refractory Bilineage Leukemia 1 1 0.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 n/a	Glioblastoma	1	1	0.0	0	n/a
Lymphoproliferative Disorder 1 2 50.0 0 n/a Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 Pilocystic Astrocytoma 1 1 100.0 0 n/a Refractory Bilineage Leukemia 1 1 0.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 n/a	Inflammatory Myofibroblastic Tumor	1	0	n/a	1	0.0
Malignant Neoplasm 1 0 n/a 1 0.0 Medulloblastoma 1 1 0.0 0 n/a Myelodysplastic Syndrome 1 1 100.0 0 n/a Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 Pilocystic Astrocytoma 1 1 100.0 0 n/a Refractory Bilineage Leukemia 1 1 0.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 n/a	Langerhan's Histocytosis	1	1	0.0	0	n/a
Medulloblastoma110.00n/aMyelodysplastic Syndrome11100.00n/aOsteosarcoma/Lymphoma10n/a10.0Pilocystic Astrocytoma11100.00n/aRefractory Bilineage Leukemia110.00n/aSoft Tissue Sarcoma11100.00n/a	Lymphoproliferative Disorder	1	2	50.0	0	n/a
Myelodysplastic Syndrome11100.00n/aOsteosarcoma/Lymphoma10n/a10.0Pilocystic Astrocytoma11100.00n/aRefractory Bilineage Leukemia110.00n/aSoft Tissue Sarcoma11100.00n/a	Malignant Neoplasm	1	0	n/a	1	0.0
Osteosarcoma/Lymphoma 1 0 n/a 1 0.0 Pilocystic Astrocytoma 1 1 100.0 0 n/a Refractory Bilineage Leukemia 1 1 0.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 n/a	Medulloblastoma	1	1	0.0	0	n/a
Pilocystic Astrocytoma11100.00n/aRefractory Bilineage Leukemia110.00n/aSoft Tissue Sarcoma11100.00n/a	Myelodysplastic Syndrome	1	1	100.0	0	n/a
Refractory Bilineage Leukemia 1 1 0.0 0 n/a Soft Tissue Sarcoma 1 1 100.0 0 n/a	Osteosarcoma/Lymphoma	1	0	n/a	1	0.0
Soft Tissue Sarcoma 1 1 100.0 0 n/a	Pilocystic Astrocytoma	1	1	100.0	0	n/a
·	Refractory Bilineage Leukemia	1	1	0.0	0	n/a
Unknown 1 1 0.0 0 n/a	Soft Tissue Sarcoma	1	1	100.0	0	n/a
	Unknown	1	1	0.0	0	n/a






Figure 1. 106 identified patients who underwent 146 procedures

Table 3. Diagnostic Yields for Individual Procedures				
Overall n = 146	Total Positive Fungal Culture/Specimens Total Procedures	27%		
BAL n = 116	BAL Positive Fungal Culture/Specimens BAL Procedures	26%		
VATS n=30	VATS Positive Fungal Culture/Specimens VATS Procedures	30%		

Results





Procedures n =16	Total Multiple Procedures Total Multiple Procedures	63%
Sequential BAL n = 7	Sequential BAL Positive Fungal Culture/Specimens Multiple BAL Procedures	57%
Sequential VATS n = 1	Sequential VATS Positive Fungal Culture/Specimens Multiple VATS Procedures	100%
Sequential BAL & VATS n = 8	Positive Sequential BAL or VATS Fungal Culture/Specimens BAL & VATS Procedures	63%




Figure 3. Comparison of fungal culture/specimen results for sequential BAL and VATS procedures conducted on the same patient within 4 weeks. "Neg" = negative culture/specimen, "Pos" = positive culture/specimen results

Table 6. Sequential BAL and VATS identified fungal species			
Sequential BAL		• Candida (NOS)	
Species identified from	Species identified from		
4 positive culture/specimens		• NOS	
Sequential VATS			
Species identified from		 Aspergillus terreus 	
1 positive culture/specimen			
		 Aspergillus terreus 	
	-BAL/+VATS	 Cladosporium 	
Sequential BAL/VATS		• NOS	
Species identified from 5 positive culture/specimens	+BAL/-VATS	• Candida glabrata	
	+DAL/-VAI3	 Cladosporium 	
	. DAL /.\/ATC	• Candida glabrata	
	+BAL/+VATS	• Phoma	

Conclusion

BAL and VATS procedures individually resulted in comparably low diagnostic yields for detection of pulmonary fungal infection in pediatric oncology patients; however, when these procedures are employed sequentially within 4 weeks of each other, the diagnostic yield increased substantially.

References

- Efrati O, et al. Fiberoptic bronchoscopy and bronchoalveolar lavage for the evaluation of pulmonary disease in children with primary immunodeficiency and cancer. Pediatr Blood Cancer 2007; 48:324-329.
- Kim K, et al. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol 2002; 71: 75-79.
- Qualter E, et al. A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantation. Biol Blood Marrow Transplant 2014; 20(8): 1229-1237.
- Rothenberg SS, et al. The safety and efficacy of thoracoscopic lung biopsy for diagnosis and treatment in infants and children. J Pediatr Surg 1996; 31(1):100-104.
- Vega-Briceño LE, et al. Utility of bronchoalveolar lavage in immunocompromised children: Diagnostic yield and complications. Arch Bronconeumol 2004; 40(12):570-574.

Acknowledgements

UT Southwestern Medical Student Research Program; Department of Surgery, UTSW; Division of Pediatric Surgery, CMC; Division of Surgical Research, CMC